<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04427384</url>
  </required_header>
  <id_info>
    <org_study_id>GTM-101</org_study_id>
    <nct_id>NCT04427384</nct_id>
  </id_info>
  <brief_title>Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)</brief_title>
  <official_title>A Multicenter Observational Study of GammaTileâ„¢ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GT Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GT Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this registry study are to evaluate real-world clinical outcomes and&#xD;
      patient reported outcomes that measure the effectiveness and safety of STaRT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients (N=600) with surgically resected (R) brain tumors of any pathology who have&#xD;
      undergone STaRT are eligible. Data collected will include local control, overall survival,&#xD;
      QOL, neurocognition, functional decline, and surgical and radiation associated AE's. Data&#xD;
      will be collected at 1, 3, 6, 9,12, 18 and 24 months, then every 6 months through 5 years.&#xD;
      RESULT: Data will be used to benchmark clinical outcomes of STaRT therapy and allow for&#xD;
      comparisons to existing standard-of-care treatments. This will be the first observational&#xD;
      registry study of R+STaRT, delivered by Cs-131 sources in permanently implanted resorbable&#xD;
      collagen tile carriers. The outcome measures captured will allow for evaluation of the&#xD;
      potential risks and benefits of this treatment approach for patients in a real-world setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Surgical Bed-Recurrence Free Survival in Metastatic Tumor Subjects</measure>
    <time_frame>12 months</time_frame>
    <description>No contrast enhancement in the area of the surgical bed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical Bed-Recurrence Free Survival in Meningioma Tumor Subjects</measure>
    <time_frame>3 years</time_frame>
    <description>No contrast enhancement in the area of the surgical bed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival in High Grade Glioma Subjects</measure>
    <time_frame>9 months</time_frame>
    <description>Median duration of survival of subjects following surgical resection of tumor</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Brain Tumor, Recurrent</condition>
  <condition>Brain Tumor</condition>
  <condition>Brain Tumor, Primary</condition>
  <condition>Brain Tumor - Metastatic</condition>
  <condition>Brain Tumor, Adult: Glioblastoma</condition>
  <condition>Brain Tumor, Adult Meningioma</condition>
  <arm_group>
    <arm_group_label>GammaTile</arm_group_label>
    <description>Patients who have received permanent implants of GammaTile radiation therapy immediately following brain tumor resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GammaTile</intervention_name>
    <description>Surgically Targeted Radiation Therapy</description>
    <arm_group_label>GammaTile</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who received STaRT intraoperatively.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who undergo maximum safe resection of intracranial neoplasm(s) AND&#xD;
             implantation of GammaTiles.&#xD;
&#xD;
          2. Willing and able to provide informed consent and to participate in all evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to undergo pre-operative and post-operative imaging for disease and implant&#xD;
             assessment.&#xD;
&#xD;
          2. Major medical or psychiatric illness, which, in the investigator's opinion would&#xD;
             prevent completion of treatment, ability to complete assessments at the time of&#xD;
             enrollment, and/or interfere with follow ups.&#xD;
&#xD;
          3. Lack of English language fluency sufficient to allow for completion of neurocognitive&#xD;
             and QOL tests (which are in English).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Misell, PhD GT Medical Technologies</last_name>
    <role>Study Director</role>
    <affiliation>GT Medical Technologies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Misell, PhD GT Medical Technologies</last_name>
    <phone>(833) 662-0044</phone>
    <email>lmisell@gtmedtech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Hall GT Medical Technologies</last_name>
    <email>ahall@gtmedtech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Wanebo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute, Baptist Health South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupesh Kotecha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Nowlan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Trusheim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clark Chen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Health</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colette Shen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vidant</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Lee, MD</last_name>
      <phone>252-847-1550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toral Patel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univertity of Texas Healthy Science Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Floyd, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

